--- title: "Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria | LABT Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/293470852.md" description: "Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) presented resistance data for its Phase 2-ready candidate Nu-3 at the PACCARB meeting. Nu-3, a Bisphosphocin® antimicrobial targeting infected diabetic foot ulcers, uses a physical mechanism to disrupt bacterial membranes, demonstrating a high barrier to resistance. The company highlighted that Nu-3 bypasses common resistance mechanisms like target mutations and efflux pumps, aligning with national efforts to combat antibiotic-resistant bacteria." datetime: "2026-07-22T04:02:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293470852.md) - [en](https://longbridge.com/en/news/293470852.md) - [zh-HK](https://longbridge.com/zh-HK/news/293470852.md) --- # Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria | LABT Stock News _Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance._ , /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB). The 27th Public Meeting of PACCARB convened on June 16, 2026, with discussion focused on the next 5-year iteration of the National Action Plan on Combating Antibiotic-Resistant Bacteria. The plan functions as a roadmap for the U.S. government to combat antimicrobial resistance (AMR) and guides the actions of the federal agencies that interface with AMR. "The rising tide of antimicrobial resistance represents one of the most severe, global crises in modern medicine, making the acceleration of novel therapeutic platforms a foremost priority," said Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics. "We are answering this national call to action by advancing our proprietary Bisphosphocin® platform. Our lead candidate, Nu-3, directly aligns with the objectives outlined by PACCARB, by targeting and disrupting bacterial membranes through a unique, physical mechanism of action. Moreover, Nu-3 has demonstrated a high barrier to resistance, positioning it as a highly differentiated candidate with potential to help address these critical national goals, while providing a valuable option for the millions of patients impacted by iDFU." Lakewood-Amedex Biotherapeutics recently announced that Nu-3 does not induce resistance in a serial passage experiment. In additional laboratory profiling, Nu-3 has demonstrated broad spectrum _in vitro_ activity against bacteria with a diverse range of resistance mechanisms, including modifications to the target of the antibiotic, direct metabolism of the agent, and efflux pump mechanisms. Antibiotic target mutation resistance examples include _vanA_ and _vanB_ variants in _E. faecalis_ and _E. faecium_, _mec_ variants in _H. influenzae_, _S. aureus_, _S. pneumoniae_, _rpoB_ variants in _K. pneumoniae_, and _PBP2x_ variants in _S. pneumoniae_. Antibiotic metabolism resistance examples include the _β-lactamase_ variants _NDM_, _ESBL_, _AmpC_, and _CRE_, in _E. cloacae_, _E. coli_, _K. pneumoniae_, _P. aeruginosa_, _P. mirabilis_, and _C. freundii_, as well as the metabolic pathway variant _sul2_ in _A. baumannii_. Efflux variant examples include metal-tetracycline/H+ antiporter in _S. epidermis_, and the benzalkonium chloride efflux pump in _S. marascens_. By bypassing these widespread resistance mechanisms, Lakewood-Amedex Biotherapeutic's platform offers a promising therapeutic avenue that directly supports the federal mandate to bolster the pipeline of innovative, resistance-evading anti-infective therapies. **About Lakewood-Amedex Biotherapeutics Inc. **Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com. **Forward-Looking Statements **This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lakewood-Amedex Biotherapeutics Inc.'s clinical development plans, regulatory strategy, anticipated trial timing, potential regulatory submissions or approvals, and the potential benefits, safety, efficacy and commercial potential of its Bisphosphocin® platform and product candidates. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks that clinical trials may not be initiated, completed or successful on expected timelines or at all; preclinical or clinical results may not be predictive of future results; product candidates may not demonstrate safety or efficacy or receive regulatory approval; and risks related to manufacturing, supply, financing and other matters described in the company's SEC filings, including under "Risk Factors." Forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to update them except as required by law. **Contact** Investor Relations Tiberend Strategic Advisors, Inc. David Irish (231) 632-0002 dirish@tiberend.com Media Relations Tiberend Strategic Advisors, Inc. Casey McDonald (646) 577-8520 cmcdonald@tiberend.com SOURCE Lakewood-Amedex Biotherapeutics Inc. ### Related Stocks - [LABT.US](https://longbridge.com/en/quote/LABT.US.md) ## Related News & Research - [Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data](https://longbridge.com/en/news/293470541.md) - [Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open](https://longbridge.com/en/news/292813307.md) - [Should you invest $3,000 in Nu Holdings right now?](https://longbridge.com/en/news/293817224.md) - [Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis](https://longbridge.com/en/news/293391923.md) - [MetroCity Bankshares Q2 profit rises on First IC deal](https://longbridge.com/en/news/293793569.md)